Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Genitourinary 2Gastrointestinal 2Breast 2Thoracic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Dermatologic 1CNS 1

Conditions

Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Breast Neoplasms 1

Interventions

Gemcitabine 9pembrolizumab 7Irinotecan 5Docetaxel 4Cisplatin 4Carboplatin 4Capecitabine 4Albumin-Bound Paclitaxel 4Paclitaxel 3Oxaliplatin 3Leucovorin 3Cyclophosphamide 3Cetuximab 3130-nm albumin-bound paclitaxel 3pazopanib 2palbociclib 2liposomal doxorubicin 2entrectinib 2alectinib 2Vinorelbine 2Trastuzumab 2Taxes 2Radiosurgery 2Oncolytic Virotherapy 2Observation 2Ipilimumab 2Fluorouracil 2Fluorodeoxyglucose F18 2Filgrastim 2Erlotinib Hydrochloride 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × trastuzumab biosimilar HLX02 × Sarcoma × Clear all
NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡